Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplasmic reticulum stress and activation of SERCA2a

American Journal of Physiology - Cell Physiology

Volumn 304, Issue 6, 2013, Pages

  Younce, Craig W ^a   Burmeister, Melissa A ^a   Ayala, Julio E ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

Glucagon like peptide 1; Heart; Hyperglycemia

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; ACTIVATING TRANSCRIPTION FACTOR 6; CASPASE 3; CYCLIC AMP DEPENDENT PROTEIN KINASE; EXENDIN 4; FORSKOLIN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; GLUCOSE REGULATED PROTEIN 78; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; HYDROGEN PEROXIDE; INITIATION FACTOR 2ALPHA; MESSENGER RNA; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHOLAMBAN; PROTEIN IRE1; REACTIVE OXYGEN METABOLITE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE 2A; THAPSIGARGIN; TUNICAMYCIN; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1; ANTIDIABETIC AGENT; ATP2A2 PROTEIN, RAT; CALCIUM BINDING PROTEIN; DDIT3 PROTEIN, RAT; EXENDIN (9 39); EXENDIN (9-39); GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE REGULATED PROTEINS; GLUCOSE-REGULATED PROTEINS; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HSPA5 PROTEIN, RAT; ISOQUINOLINE DERIVATIVE; MEMBRANE PROTEIN; N (2 (4 BROMOCINNAMYLAMINO)ETHYL) 5 ISOQUINOLINESULFONAMIDE; N-(2-(4-BROMOCINNAMYLAMINO)ETHYL)-5-ISOQUINOLINESULFONAMIDE; PEPTIDE; PEPTIDE FRAGMENT; PROTEIN KINASE INHIBITOR; SULFONAMIDE; VENOM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ATTENUATION; CELL DEATH; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE; HYPERGLYCEMIA; MOLECULAR MIMICRY; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; SARCOPLASMIC RETICULUM; UNFOLDED PROTEIN RESPONSE; ANIMAL; BIOSYNTHESIS; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

RATTUS; THERA;

ANIMALS; APOPTOSIS; CALCIUM-BINDING PROTEINS; CELLS, CULTURED; DIABETIC CARDIOMYOPATHIES; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; FORSKOLIN; GLUCOSE; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HYDROGEN PEROXIDE; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; ISOQUINOLINES; MEMBRANE PROTEINS; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PEPTIDE FRAGMENTS; PEPTIDES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RATS; RECEPTORS, GLUCAGON; RNA, MESSENGER; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SULFONAMIDES; THAPSIGARGIN; TRANSCRIPTION FACTOR CHOP; TUNICAMYCIN; UNFOLDED PROTEIN RESPONSE; VENOMS;

MLCS; MLOWN;

EID: 84877252041     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00248.2012     Document Type: Article

References (61)

1. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 117: 2340-2350, 2008.
2. Basu R, Oudit GY, Wang X, Zhang L, Ussher JR, Lopaschuk GD, Kassiri Z. Type 1 diabetic cardiomyopathy in the Akita (Ins2WT/C96Y) mouse model is characterized by lipotoxicity and diastolic dysfunction with preserved systolic function. Am J Physiol Heart Circ Physiol 297: H2096-H2108, 2009.
3. Belke DD, Dillmann WH. Altered cardiac calcium handling in diabetes. Curr Hypertens Rep 6: 424-429, 2004.
4. Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X, Kang YJ. Attenuation by metallothionein of early cardiac cell death via suppression of mito-chondrial oxidative stress results in a prevention of diabetic cardiomyop-athy. J Am Coll Cardiol 48: 1688-1697, 2006.
5. Clark RJ, McDonough PM, Swanson E, Trost SU, Suzuki M, Fukuda M, Dillmann WH. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem 278: 44230-44237, 2003.
6. Cunha DA, Ladriere L, Ortis F, Igoillo-Esteve M, Gurzov EN, Lupi R, Marchetti P, Eizirik DL, Cnop M. Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes 58: 2851-2862, 2009.
7. Desco MC, Asensi M, Marquez R, Martinez-Valls J, Vento M, Pallardo FV, Sastre J, Vina J. Xanthine oxidase is involved in free radical production in type 1 diabetes: protection by allopurinol. Diabetes 51: 1118-1124, 2002.
8. Djouder N, Tuerk RD, Suter M, Salvioni P, Thali RF, Scholz R, Vaahtomeri K, Auchli Y, Rechsteiner H, Brunisholz RA, Viollet B, Makela TP, Wallimann T, Neumann D, Krek W. PKA phosphorylates and inactivates AMPKalpha to promote efficient lipolysis. EMBO J 29: 469-481, 2010.
9. Drucker DJ. The biology of incretin hormones. Cell Metab 3: 153-165, 2006.
10. Duncan JG. Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta 1813: 1351-1359, 2011.
11. Dutta K, Carmody MW, Cala SE, Davidoff AJ. Depressed PKA activity contributes to impaired SERCA function and is linked to the pathogenesis of glucose-induced cardiomyopathy. J Mol Cell Cardiol 34: 985-996, 2002.
12. Favaro E, Granata R, Miceli I, Baragli A, Settanni F, Cavallo Perin P, Ghigo E, Camussi G, Zanone MM. The ghrelin gene products and exendin-4 promote survival of human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-kinase/Akt, extra-cellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signalling pathways. Diabetologia 55: 1058-1070, 2012.
13. Fiordaliso F, Bianchi R, Staszewsky L, Cuccovillo I, Doni M, Lara-gione T, Salio M, Savino C, Melucci S, Santangelo F, Scanziani E, Masson S, Ghezzi P, Latini R. Antioxidant treatment attenuates hyper-glycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol 37: 959-968, 2004.
14. Gilman CP, Perry T, Furukawa K, Grieg NH, Egan JM, Mattson MP. Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J Neurochem 87: 1137-1144, 2003.
15. Groenendyk J, Sreenivasaiah PK, Kim do H, Agellon LB, Michalak M. Biology of endoplasmic reticulum stress in the heart. Circ Res 107: 1185-1197, 2010.
16. Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, Parker TG, Huang Q, Drucker DJ, Husain M. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 144: 2242-2252, 2003.
17. Hamanaka RB, Bennett BS, Cullinan SB, Diehl JA. PERK and GCN2 contribute to eIF2alpha phosphorylation and cell cycle arrest after activa-tion of the unfolded protein response pathway. Mol Biol Cell 16: 5493-5501, 2005.
18. Holz GG. Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 53: 5-13, 2004.
19. Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5=-adenosine monophosphate-dependent protein kinase A-and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144: 1444-1455, 2003.
20. Inoguchi T, Sonta T, Tsubouchi H, Etoh T, Kakimoto M, Sonoda N, Sato N, Sekiguchi N, Kobayashi K, Sumimoto H, Utsumi H, Nawata H. Protein kinase C-dependent increase in reactive oxygen species (ROS) production in vascular tissues of diabetes: role of vascular NAD(P)H oxidase. J Am Soc Nephrol 14: S227-S232, 2003.
21. Karakikes I, Kim M, Hadri L, Sakata S, Sun Y, Zhang W, Chemaly ER, Hajjar RJ, Lebeche D. Gene remodeling in type 2 diabetic cardio-myopathy and its phenotypic rescue with SERCA2a. PLos One 4: e6474, 2009.
22. Kimura R, Okouchi M, Fujioka H, Ichiyanagi A, Ryuge F, Mizuno T, Imaeda K, Okayama N, Kamiya Y, Asai K, Joh T. Glucagon-like peptide-1 (GLP-1) protects against methylglyoxal-induced PC12 cell ap-optosis through the PI3K/Akt/mTOR/GCLc/redox signaling pathway. Neuroscience 162: 1212-1219, 2009.
23. Kranias EG, Hajjar RJ. Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res 110: 1646-1660, 2012.
24. Laviola L, Leonardini A, Melchiorre M, Orlando MR, Peschechera A, Bortone A, Paparella D, Natalicchio A, Perrini S, Giorgino F. Gluca-gon-like peptide-1 counteracts oxidative stress-dependent apoptosis of human cardiac progenitor cells by inhibiting the activation of the c-Jun N-terminal protein kinase signaling pathway. Endocrinology 153: 5770-5781, 2012.
25. Li Y, Feng Q, Arnold M, Peng T. Calpain activation contributes to hyperglycaemia-induced apoptosis in cardiomyocytes. Cardiovasc Res 84: 100-110, 2009.
26. Li Z, Zhang T, Dai H, Liu G, Wang H, Sun Y, Zhang Y, Ge Z. Endoplasmic reticulum stress is involved in myocardial apoptosis of streptozocin-induced diabetic rats. J Endocrinol 196: 565-572, 2008.
27. Liang CP, Han S, Li G, Tabas I, Tall AR. Impaired MEK signaling and SERCA expression promote ER stress and apoptosis in insulin-resistant macrophages and are reversed by exenatide treatment. Diabetes 61: 2609-2620, 2012.
28. Lochner A, Moolman JA. The many faces of H89: a review. Cardiovasc Drug Rev 24: 261-274, 2006.
29. Lytton J, Westlin M, Hanley MR. Thapsigargin inhibits the sarcoplas-mic or endoplasmic reticulum Ca-ATPase family of calcium pumps. J Biol Chem 266: 17067-17071, 1991.
30. Malhotra JD, Kaufman RJ. Endoplasmic reticulum stress and oxidative stress: a vicious cycle or a double-edged sword? Antioxid Redox Signal 9: 2277-2293, 2007.
31. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zoure-lias L, Stolarski C, Shen YT, Shannon RP. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventric-ular performance in conscious dogs with pacing-induced dilated cardio-myopathy. Circulation 110: 955-961, 2004.
32. Noyan-Ashraf MH, Momen MA, Ban K, Sadi AM, Zhou YQ, Riazi AM, Baggio LL, Henkelman RM, Husain M, Drucker DJ. GLP-1R agonist liraglutide activates cytoprotective pathways and improves out-comes after experimental myocardial infarction in mice. Diabetes 58: 975-983, 2009.
33. Noyan-Ashraf MH, Shikatani EA, Schuiki I, Mukovozov I, Wu J, Li RK, Volchuk A, Robinson LA, Billia F, Drucker DJ, Husain M. A glucagon-like peptide-1 analogue reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 127: 74-85, 2012.
34. Okerson T, Chilton RJ. The cardiovascular effects of GLP-1 receptor agonists. Cardiovasc Ther 30: e146-e55, 2012.
35. Qin Z, Sun Z, Huang J, Hu Y, Wu Z, Mei B. Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42). Neurosci Lett 444: 217-221, 2008.
36. Quoyer J, Longuet C, Broca C, Linck N, Costes S, Varin E, Bockaert J, Bertrand G, Dalle S. GLP-1 mediates antiapoptotic effect by phos-phorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells. J Biol Chem 285: 1989-2002, 2010.
37. Raab EL, Vuguin PM, Stoffers DA, Simmons RA. Neonatal exendin-4 treatment reduces oxidative stress and prevents hepatic insulin resistance in intrauterine growth-retarded rats. Am J Physiol Regul Integr Comp Physiol 297: R1785-R1794, 2009.
38. Ravassa S, Zudaire A, Carr RD, Diez J. Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am J Physiol Heart Circ Physiol 300: H1361-H1372, 2011.
39. Rothermel BA, Hill JA. Myocyte autophagy in heart disease: friend or foe? Autophagy 3: 632-634, 2007.
40. San Martin A, Du P, Dikalova A, Lassegue B, Aleman M, Gongora MC, Brown K, Joseph G, Harrison DG, Taylor WR, Jo H, Griendling KK. Reactive oxygen species-selective regulation of aortic inflammatory gene expression in Type 2 diabetes. Am J Physiol Heart Circ Physiol 292: H2073-H2082, 2007.
41. Sarkar R, Basu S, Sharma RC. Neonatal and infantile erythrodermas. Arch Dermatol 137: 822-823, 2001.
42. Schisano B, Harte AL, Lois K, Saravanan P, Al-Daghri N, Al-Attas O, Knudsen LB, McTernan PG, Ceriello A, Tripathi G. GLP-1 analogue, Liraglutide protects human umbilical vein endothelial cells against high glucose induced endoplasmic reticulum stress. Regul Pept 174: 46-52, 2012.
43. Shen E, Li Y, Shan L, Zhu H, Feng Q, Arnold JM, Peng T. Rac1 is required for cardiomyocyte apoptosis during hyperglycemia. Diabetes 58: 2386-2395, 2009.
44. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12: 694-699, 2006.
45. Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfu-sion injury in rat heart. Regul Pept 146: 243-249, 2008.
46. Szegezdi E, Logue SE, Gorman AM, Samali A. Mediators of endoplas-mic reticulum stress-induced apoptosis. EMBO Rep 7: 880-885, 2006.
47. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 13: 184-190, 2011.
48. Taha M, Lopaschuk GD. Alterations in energy metabolism in cardiomy-opathies. Ann Med 39: 594-607, 2007.
49. Tang WH, Cheng WT, Kravtsov GM, Tong XY, Hou XY, Chung SK, Chung SS. Cardiac contractile dysfunction during acute hyperglycemia due to impairment of SERCA by polyol pathway-mediated oxidative stress. Am J Physiol Cell Physiol 299: C643-C653, 2010.
50. Tarquini R, Lazzeri C, Pala L, Rotella CM, Gensini GF. The diabetic cardiomyopathy. Acta Diabetol 48: 173-181, 2011.
51. 2+ channel mRNA in streptozotocin-induced diabetic rat heart. J Mol Cell Cardiol 32: 655-664, 2000.
52. Tews D, Lehr S, Hartwig S, Osmers A, Paslack W, Eckel J. Antiapoptotic action of exendin-4 in INS-1 beta cells: comparative protein pattern analysis of isolated mitochondria. Horm Metab Res 41: 294-301, 2009.
53. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 53: 501-510, 2009.
54. Voulgari C, Papadogiannis D, Tentolouris N. Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Manag 6: 883-903, 2010.
55. 2+ currents via activation of the cAMP-dependent protein kinase A pathway. Cardiovasc Diabetol 10: 6, 2011.
56. Ye Y, Birnbaum Y. Cyclic AMP-mediated pleiotropic effects of gluca-gon-like peptide-1 receptor activation. Focus on "Exendin-4 attenuates high glucose-induced cardiomyocyte apoptosis via inhibition of endoplas-mic reticulum stress and activation of SERCA2a." Am J Physiol Cell Physiol (January 30, 2013). doi:10.1152/ajpcell.00419.2012.
57. Younce CW, Kolattukudy PE. MCP-1 causes cardiomyoblast death via autophagy resulting from ER stress caused by oxidative stress generated by inducing a novel zinc-finger protein, MCPIP. Biochem J 426: 43-53, 2010.
58. Younce CW, Wang K, Kolattukudy PE. Hyperglycaemia-induced car-diomyocyte death is mediated via MCP-1 production and induction of a novel zinc-finger protein MCPIP. Cardiovasc Res 87: 665-674, 2010.
59. Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, Li H, Pipeleers D, Ling Z, Drucker DJ. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic retic-ulum stress. Cell Metab 4: 391-406, 2006.
60. Zhang K, Kaufman RJ. From endoplasmic-reticulum stress to the in-flammatory response. Nature 454: 455-462, 2008.
61. Zhong Y, Ahmed S, Grupp IL, Matlib MA. Altered SR protein expres-sion associated with contractile dysfunction in diabetic rat hearts. Am J Physiol Heart Circ Physiol 281: H1137-H1147, 2001.